Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR 60 3-1 Month Momentum % is -36.40% as of Aug. 14, 2026. GuruFocus rates BNR with a GF Score™ of 60/100 and a GF Value™ of $7.46 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Burning Rock Biotech ranks worse than 89.25% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-14), Burning Rock Biotech's 3-1 Month Momentum % is -36.40%.
The industry rank for Burning Rock Biotech's 3-1 Month Momentum % or its related term are showing as below:
BNR's 3-1 Month Momentum % is ranked worse than 89.25% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.455
vs BNR: -36.40
Burning Rock Biotech (NAS:BNR) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Burning Rock Biotech 3-1 Month Momentum % Related Terms
BNR vs XGN, PRPO, IDXG: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's 3-1 Month Momentum % falls into.
Burning Rock Biotech (NAS:BNR) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (BNR) has a 3-1 Month Momentum % of -36.40% as of Aug. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #191 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 89.3%.
Is Burning Rock Biotech's 3-1 Month Momentum % too high?
Burning Rock Biotech's current 3-1 Month Momentum % is -36.40%. Based on the distribution chart, Burning Rock Biotech ranks #191 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's 3-1 Month Momentum % compare to XGN and PRPO?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #191 out of 214 companies for 3-1 Month Momentum %. This places Burning Rock Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current 3-1 Month Momentum % is -36.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.46, compared to a current price of $9.29 — trading 24.5% above its estimated fair value. The current 3-1 Month Momentum % is -36.40%. Burning Rock Biotech's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current 3-1 Month Momentum % is -36.40% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.29 is trading 24.5% above its estimated GF Value™ of $7.46.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
3-1 Month Momentum %: -36.40%
GF Value™: $7.46 vs. price of $9.29 (24.5% above fair value)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
60GF Score
Get the complete analysis for BNR
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
